Dr. Reddy's Labs Q3 FY26 Results: Total Income at ₹15,148 Crore, Net Profit ₹2,043 Crore
Dr. Reddy's Laboratories reported Q3 FY26 consolidated results. Total income for nine months reached ₹15,148 crore, with net profit after tax at ₹1,529 crore. For the quarter, total income was ₹5,398 crore and net profit after tax was ₹579 crore. The Board recommended an interim dividend of ₹20 per share.
The announcement pertains to the company's financial performance and dividend declaration, which are material events for investors and stakeholders.
The company reported positive financial results with increased income and profit for the quarter and nine months, along with a recommended interim dividend.
Dr. Reddy's Laboratories Limited has announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company reported a total income from operations of ₹15,148 crore for the nine-month period and ₹5,398 crore for the quarter. The net profit before tax for the nine months stood at ₹2,043 crore, while for the quarter it was ₹772 crore. The net profit after tax for the nine months was ₹1,529 crore, and ₹579 crore for the quarter. Total comprehensive income for the nine months was ₹1,502 crore and ₹570 crore for the quarter.
The company's paid-up equity share capital remained at ₹200 crore. Total reserves stood at ₹21,775 crore. Basic and diluted Earnings Per Share (EPS) for the nine-month period were ₹76.45 and ₹76.45 respectively, and for the quarter, they were ₹8.95 and ₹8.95 respectively.
The Board of Directors has recommended an interim dividend of ₹20 per share (200% on face value of equity share of ₹10 each). The financial results were approved by the Board of Directors at their meeting held on January 21, 2026, and have been subjected to a limited review by the statutory auditors.
What to do with a filing like this
Dr. Reddy's Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dr. Reddy's Laboratories Limited. Read the original for the full detail.